• Share Purchase Plan significantly oversubscribed, raising A$5 million
• Follows successful A$75 million placement announced in September 2025
• Shares issued at A$2.05 each, same price as the placement

Artrya Limited (ASX: AYA), a medical technology company commercializing its Salix® AI-powered cloud platform for the assessment and management of coronary artery disease, has completed its Share Purchase Plan (SPP). The SPP was strongly supported and closed early on 26 September 2025, significantly oversubscribed. Eligible applications received totaled approximately A$8.7 million, with the company scaling back applications on a pro-rata basis to raise around A$5 million. A total of 2,438,872 new fully paid ordinary shares will be issued pursuant to the SPP, at A$2.05 per share, which is the same price as the A$75 million placement announced in September 2025. The strong support for the SPP follows the successful placement, offering all eligible shareholders the opportunity to acquire shares at the same price. Excess application money resulting from the scale back will be refunded to applicants, and the company encourages applicants to ensure their direct credit details are provided to facilitate the timely provision of any refunds.